News
FDA to Crackdown on Non-Approved GLP-1 Drugs
The FDA is intensifying actions against non-FDA-approved GLP-1 drugs. Learn about the implications for pharmacists and healthcare professionals.
FDA Launches PreCheck Pilot Program, Aimed at Strengthening U.S. Drug Manufacturing
FDA's new PreCheck pilot program aims to boost domestic drug manufacturing through streamlined regulatory pathways and early facility engagement.
Roche's CT-388 Achieves 22.5% Weight Loss in Phase 2 Trial
Roche's investigational obesity drug CT-388 demonstrated 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 trial, advancing to Phase 3 studies.
New Evidence Links Targeted Urate-Lowering to Cardiovascular Benefits in Gout
Study links targeted urate-lowering in gout with reduced cardiovascular risk, highlighting its importance for pharmacists.
Centanafadine: First Triple Reuptake Inhibitor for ADHD Nears FDA Approval
An overview of centanafadine, a novel triple reuptake inhibitor for ADHD, covering its mechanism, clinical trials, safety, FDA status, and comparison with existing therapies.
Walmart Elevates Pharmacy Technician Roles and Pay, Benefiting Pharmacists and Students
Walmart's recent investment in pharmacy technicians enhances career opportunities and positively impacts pharmacists and pharmacy students.
Lyra Therapeutics Suspends Development of LYR-210 for Chronic Rhinosinusitis Despite Positive Trial Results
Lyra Therapeutics halts development of LYR-210 for chronic rhinosinusitis despite positive Phase 3 results, cutting workforce and exploring strategic alternatives.
FDA Removes REMS Program for Clozapine Despite Neutropenia Risk
FDA eliminates mandatory safety program for clozapine, citing access concerns while acknowledging ongoing neutropenia risk for patients.
UnitedHealthcare CEO Brian Thompson Fatally Shot in New York City
UnitedHealthcare CEO Brian Thompson, 50, was fatally shot in a targeted attack outside a New York City hotel on December 4, 2024. The suspect remains at large as investigations continue.
Genentech to Discontinue Fuzeon® (Enfuvirtide) Amid Evolving HIV Treatment Landscape
Genentech discontinues Fuzeon (enfuvirtide) by February 2025 as advanced HIV treatments emerge. Learn how healthcare providers should transition patients to newer therapies.